Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
10/2000
10/19/2000CA2368655A1 Dry formulation for transcutaneous immunization
10/19/2000CA2368369A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000CA2366794A1 Channel forming toxins as antiviral agents
10/19/2000CA2366520A1 Anti-bacterial vaccine compositions
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365915A1 Recombinant toxin a/toxin b vaccine against clostridium difficile
10/19/2000CA2365914A1 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/19/2000CA2365912A1 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
10/19/2000CA2365910A1 Human proteins and polynucleotides encoding them
10/19/2000CA2364690A1 Novel transduction molecules and methods for using same
10/19/2000CA2364675A1 Methods of inducing cancer cell death and tumor regression
10/19/2000CA2364541A1 Genes associated with diseases of the kidney
10/19/2000CA2360318A1 A second mammalian tankyrase
10/18/2000EP1044273A2 COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE
10/18/2000EP1044267A2 Novel nucleic acid and polypeptide with homology to the tnf-receptors
10/18/2000EP1044266A2 Human signal peptide-containing proteins
10/18/2000EP1044263A2 CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
10/18/2000EP1044218A1 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
10/18/2000EP1044212A1 Human fk506 binding proteins
10/18/2000EP1044211A1 36 human secreted proteins
10/18/2000EP1044022A2 Compositions and methods for targeted delivery of factors
10/18/2000EP1044020A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/18/2000EP1044019A1 Methods and compositions for desensitisation
10/18/2000EP1044018A2 Tumour vaccines for muc1-positive carcinomas
10/18/2000EP1044014A1 Agent for treating allergic or hypersensitivity condition
10/18/2000EP1044013A2 Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
10/18/2000EP1044003A1 Compositions and methods for use in ischemia-reperfusion and endotoxin-related tissue injury
10/18/2000EP0577666B1 Polypeptides from mycobacterium paratuberculosis
10/18/2000EP0467932B1 Urokinase-type plasminogen activator receptor
10/18/2000CN1270635A Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these protein
10/18/2000CN1270632A APPIL-a novel protein with growth effects
10/18/2000CN1270061A 弯曲菌疫苗 Campylobacter vaccine
10/18/2000CN1057533C Method for producing clostridium perfringers vaccines
10/18/2000CN1057532C Process for purifying hepatitis B viral surface antigen comprising PRES2 peptide
10/17/2000US6133433 Nucleotide sequence; probes used for diagnosis; recombinant production of proteins; vaccines
10/17/2000US6133427 Anti-human calcitonin monoclonal antibodies and an immunoassay utilizing said antibodies
10/17/2000US6133423 Don-1 gene and polypeptides and uses therefor
10/17/2000US6133418 Synthetic peptide inhibitors of HIV transmission
10/17/2000US6133244 Method for immunization against hepatitis B
10/17/2000US6133029 Replication defective viral vectors for infecting human cells
10/17/2000US6133025 Nucleic acid for episomal replication in mammalian cells; includes a cis-acting origin of replication sequence and the nuclear antigen 1 sequence linked to a promoter; for gene therapy
10/17/2000US6133017 Attenuated strain of Leishmania
10/17/2000US6133015 HHV-8+ lymphoma cell line which is HIV-, CMV-, EBV-, and which produces large amounts of uncontaminated HHV-8 virus
10/17/2000US6133006 Nucleotide sequence coding an enzmatic polypeptide associated with signal transduction; for the diagnosis and treatment of osteoporosis, inflammation, skin disorders, asthma, nervous system disorders, cancer, eating disorders and infections
10/17/2000US6133005 Enzymatic protein; for the treatment of nervous system disorders associated with thamine vitamin deficiency
10/17/2000US6132980 Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes
10/17/2000US6132970 Rearranging nucleotide sequences; extending chains of nucleotide sequence with regions of both homogeneity and heterogeneity in multiple cycles, screening rearranged nucleotide sequences to detect desired properties
10/17/2000US6132966 Enzymatic nucleic acid which specifically prevents viral replication; for the treatment of transformed hepatocytes and suppression of viral infection humans, animals and primates
10/17/2000US6132789 For vaccine formulations as adjuvants and/or delivery systems, to enhance immune response to immunogens in animal such as human
10/17/2000US6132759 Medicaments containing gelatin cross-linked with oxidized polysaccharides
10/17/2000US6132734 Cloning of mite allergens
10/17/2000US6132733 Ringworm vaccine
10/17/2000US6132732 Parvovirus capsids
10/17/2000US6132723 Oligosaccharide hapten covalently coupled to carrier protein
10/17/2000US6132721 Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same
10/17/2000US6132720 Immunogens against gonadotropin releasing hormone
10/17/2000US6132718 Using a vaccine comprising antibodies and anti-idiotype antibodies that mimic an epitope of antigen that is associated with a tumor or infectious agent.
10/17/2000US6132709 Administering a fusobacterium necrophorum bacterin
10/17/2000CA2117303C Anti-cancer immunotherapeutic vector constructs
10/17/2000CA2104899C Antibodies to plasmodium falciparum
10/17/2000CA1341123C Filamentous hemagglutinin of b. pertussis
10/12/2000WO2000060357A1 Tandem immuno-assay for cancer
10/12/2000WO2000060127A1 Retrovirus associated with primary sclerosing cholangitis
10/12/2000WO2000060106A1 Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
10/12/2000WO2000060102A2 Bacterial fimbrial system for presentation of heterologous peptide sequences
10/12/2000WO2000060100A1 Dsp-9 dual-specificity map kinase phosphatase
10/12/2000WO2000060090A1 Compounds and methods for the diagnosis and treatment of b. microti infection
10/12/2000WO2000060084A1 Compositions and methods for the therapy and diagnosis of prostate cancer
10/12/2000WO2000060080A2 Molecules of the immune system
10/12/2000WO2000060077A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
10/12/2000WO2000060076A2 Compositions for the treatment and diagnosis of breast cancer and methods for their use
10/12/2000WO2000060050A2 Recombinant influenza viruses for vaccines and gene therapy
10/12/2000WO2000059944A1 A monoclonal antibody against estrogen stimulated leucine aminopeptidase
10/12/2000WO2000059943A2 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE
10/12/2000WO2000059942A2 Human obesity protein binding protrein-2 homolog and uses thereof
10/12/2000WO2000059941A1 Purposeful movement of human migratory cells away from an agent source
10/12/2000WO2000059935A1 Anti-apoptotic fusion polypeptide
10/12/2000WO2000059930A1 A method of treating cancer
10/12/2000WO2000059539A1 Method and means for treating post-polio syndrome
10/12/2000WO2000059538A2 Antigen-specific induction of peripheral immune tolerance
10/12/2000WO2000059534A1 Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
10/12/2000WO2000059525A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
10/12/2000WO2000059515A2 Immunomodulating polymers
10/12/2000WO2000059514A1 Yeaz
10/12/2000WO2000059473A1 Compositions and methods for treating lymphoma
10/12/2000WO2000037494A3 Chlamydia trachomatis antigens
10/12/2000WO2000035939A3 Connective tissue growth factor fragments and methods and uses thereof
10/12/2000WO2000034482A3 Novel compounds derived from neisseria meningitidis
10/12/2000WO2000034445A3 Live attenuated venezuelan equine encephalitis vaccine
10/12/2000WO2000033874A3 Boron neutron capture therapy using pre-targeting methods
10/12/2000WO2000033871A3 Use of human prostate tumour cell lines in cancer treatment
10/12/2000WO2000033869A3 Use of human prostrate cell lines in cancer treatment
10/12/2000WO2000032227A3 Ordered molecular presentation of antigens, method of preparation and use
10/12/2000WO2000029582A3 Cell surface receptor antigen vaccines
10/12/2000WO2000025722A3 ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
10/12/2000WO2000020587A3 Cancer associated antigens and uses therefor
10/12/2000WO2000020446A3 Bax-mediated apoptosis modulating reagents and methods
10/12/2000WO2000020027A3 Methods for therapeutic vaccination
10/12/2000WO2000018918A9 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
1 ... 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 ... 1823